Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (711-720 of 853) with videos related to

Pageof 86
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unitKhurum Khan, Joo Ern Ang, Naureen Starling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
British Journal of Cancer|February 13, 2001
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerP A Vasey, R Atkinson, R Coleman, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigatorsChristophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancerP A Vasey, L N Shulman, S Campos, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 15, 2016
The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and FailureC L Hopkinson, V Romano, R A Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 12, 2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I UnitR Sundar, A Custodio, A Petruckevich, et al.
The British Journal of Surgery|September 1, 1984
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-CD Cunningham, M Soukop, C S McArdle, et al.
Pageof 86

Showing results (711-720 of 853) with videos related to

Sort By:
Pageof 86
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unitKhurum Khan, Joo Ern Ang, Naureen Starling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
British Journal of Cancer|February 13, 2001
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerP A Vasey, R Atkinson, R Coleman, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigatorsChristophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancerP A Vasey, L N Shulman, S Campos, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 15, 2016
The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and FailureC L Hopkinson, V Romano, R A Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 12, 2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I UnitR Sundar, A Custodio, A Petruckevich, et al.
The British Journal of Surgery|September 1, 1984
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-CD Cunningham, M Soukop, C S McArdle, et al.
Pageof 86